100% Quality Guarantee
PhD-Level Technical Support
Faralimomab Antibody - SDS-PAGE
Key Features

Faralimomab Antibody (GXBS00034)

SKU GXBS00034
Product Type Research Grade Biosimilar
Antibody Type Monoclonal
Host Species Mouse
Reactivity Human
Applications ELISA, FACS, Functional assay, Research in vivo
Isotype IgG1-nd
$409 - $1,138

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Faralimomab Antibody

Faralimomab Antibody is a research-grade biosimilar monoclonal antibody targeting Interferon alpha/beta receptor 1. It is a mouse IgG1-nd antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% as determined by SDS-PAGE. For research use only.

Interferon alpha/beta receptor 1 (beta receptor 1,Cytokine receptor family 2 member 1,Cytokine receptor class-II member 1,CRF2-1,IFN-R-1,IFNAR1,IFNAR,IFN-alpha/beta receptor 1,Type I interferon receptor 1) is a ~63 kDa protein. Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors. STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose